BlackRock Amends Madrigal Pharma Stake, Maintains Institutional Holding
Ticker: MDGL · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1157601
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns Madrigal Pharma, showing continued institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Madrigal Pharmaceuticals, Inc. as of December 31, 2023. This filing indicates that BlackRock continues to be a significant institutional holder, which can provide a sense of stability and institutional confidence for current and prospective investors in Madrigal Pharmaceuticals.
Why It Matters
Large institutional ownership by firms like BlackRock can signal confidence in a company's long-term prospects, potentially influencing other investors and stock stability.
Risk Assessment
Risk Level: low — This filing is routine and indicates stable institutional ownership, posing minimal immediate risk to investors.
Analyst Insight
Investors should note BlackRock's continued institutional presence, but this filing alone doesn't provide new actionable insights beyond confirming stable institutional ownership. Further research into Madrigal's fundamentals and BlackRock's specific stake percentage would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Madrigal Pharmaceuticals, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the date the SC 13G/A was filed
Forward-Looking Statements
- BlackRock will likely maintain a significant stake in Madrigal Pharmaceuticals throughout 2024. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating a change or update to a previous filing by a passive institutional investor.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., a major institutional investment manager.
What company's shares are the subject of this filing?
The subject company for this filing is Madrigal Pharmaceuticals, Inc.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).